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ABSTRACT
Introduction: This study aimed to demonstrate
the clinical utility of non-invasive multigene
Cxbladder urine tests in reducing the overall
number of diagnostic tests and invasive proce-
dures used in the clinical evaluation of patients
presenting with microhematuria, a key symp-
tom of urothelial carcinoma (UC). There is a
belief that using non-invasive molecular diag-
nostic tests in patients with hematuria may lead
to patients undergoing unnecessary and costly
invasive procedures that can cause adverse
events and decrease patient quality of life. The
objective of this study was to determine whe-
ther or not this was the case, using Cxbladder.
Methods: Data from 396 patient-by-urologist
interactions generated 792 decision points from
a standardized cohort of 33 patients evaluated
by 12 urologists. Participant physicians recom-
mended a selection of tests and procedures
based on referral data, then reviewed and
amended their recommendations in the context
of diagnostic information from Cxbladder used
in the Triage and Triage and Detect clinical
modalities.
Results: All urologists changed their diagnostic
behavior in at least one patient case with the
addition of Cxbladder results. The total number
of diagnostic procedures was reduced by 5% and
25% following disclosure of results from
Cxbladder in the Triage and the Triage and
Detect modalities, respectively. The total num-
ber of requested invasive procedures was
reduced from 425 at referral to 379 (-11%) and
292 (-31%) following disclosure of Cxbladder
information in the Triage and Triage and Detect
modalities, respectively.
Conclusions: Urologists made compelling
changes to their clinical decision-making when
they were provided with Cxbladder results for
patients presenting with hematuria. Cxbladder
provides an increase in clinical utility by
focusing the use of invasive diagnostic proce-
dures to appropriate patients, reducing both the
total number and number of invasive proce-
dures used in the clinical management of
patients with hematuria, thereby improving the
diagnostic experience and outcomes for
patients.
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INTRODUCTION
Clinical utility for a molecular diagnostic test
refers to a demonstration of its usefulness
within a clinical pathway (i.e. the test’s ability
to influence patient care management), and
includes the test’s impact on patient well-be-
ing, avoidance of unnecessary or detrimental
treatment, and mitigating collateral adverse
events (e.g. effects of a treatment or invasive
procedure on a patient that could have been
avoided, and the additional costs incurred
thereof) [1–3]. This can also be extended to the
impact of the investigation on the patient, as
determined by the level of invasiveness.
As an example, blood in the urine, or
hematuria, is a common finding in clinical
practice which is most commonly associated
with benign causes [4]. However, hematuria can
be a symptom of urothelial carcinoma (UC),
and as the degree of hematuria is not correlated
with disease stage or grade [5–7], the American
Urological Association (AUA) and American
College of Physicians recommend that all
patients with asymptomatic microscopic
hematuria (AMH) undergo a full urological
work-up, including invasive procedures, such as
cystoscopy and contrast computed tomography
(CT) scans [8, 9].
As non-invasive molecular diagnostic tests
for UC have yet to clearly demonstrate utility in
changing clinical practice and improving out-
comes for patients with hematuria, concern has
been expressed that results derived from such
tests may encourage the unnecessary use of
invasive and costly diagnostic procedures to
either confirm or rule out UC in the absence of a
clear benign cause of hematuria [8–11]. Per-
forming invasive procedures also increases the
risk of a patient experiencing an adverse event
during the diagnostic process [8, 12–17].
Taking these factors into consideration, a
framework was developed to assess the clinical
utility of Cxbladder, a non-invasive test per-
formed on a single unfractionated urine sample,
using a concurrent clinical decision-making
approach. Using a single voided urine sample,
Cxbladder measures the expression of five
genomic markers (IGF, HOXA, MDK, CDC and
IL8R gene expression) in its Detect modality,
while data from these genomic markers and
clinical variables (age, gender, frequency of
macrohematuria and smoking history) are con-
sidered in its Triage clinical modality. Cxblad-
der is used to identify patients who have a low
risk of UC and may not require a full urological
work-up (Triage clinical modality), and patients
with a high probability of UC (Detect clinical
modality) [18, 19]. Cxbladder has been vali-
dated for ruling out UC in 40% of patients with
macrohematuria when used in the Triage
modality (sensitivity 0.95; negative predictive
value 0.98) [18], and has proven effective at
separating samples from healthy patients and
those with UC in the Detect modality (speci-
ficity 0.85; sensitivity 0.82) [19, 20].
Using a decision-making approach, urolo-
gists in the present study were asked to make
clinical decisions in the context of referral
data from real-life cases of patients presenting
with hematuria. These physicians were then
provided with new diagnostics data from
Cxbladder tests and given an opportunity to
change their clinical decisions, without any
risk of detriment to patient care or clinical
outcome.
The aim of this study was to investigate the
clinical utility of Cxbladder when used in the
urological evaluation of patients presenting
with hematuria and no obvious benign cause by
assessing the change in clinical decision-making
in the context of results from Cxbladder in the
Triage and Detect modalities. Specifically, the
study objective was to identify and quantify
changes in urologist behavior once information
from Cxbladder testing was added to the pri-
mary clinical case data from patients with
microhematuria and the possibility of UC, who
underwent invasive diagnostic procedures as
part of a real-world full urological work-up. It
was expected that disclosing information from
Cxbladder in the Triage and Triage and Detect
modalities would reduce the number and/or
extent of the use of total investigative proce-





A sample population of urologists (participant
physicians) with experience in the use and
application of Cxbladder in their clinical set-
tings were individually informed of the clinical
purpose of Cxbladder in both the Triage and
Detect modalities. Cases were individually
evaluated in the same sequence under the
supervision of a study coordinator. Participant
physicians were asked to review and recom-
mend diagnostic procedures for each case based
on the patient’s evaluation from normal referral
data.
Requested diagnostic tests and procedures
were recorded following a standardized pro-
tocol, demonstrated by the coordinators prior
to beginning the study. Participant physicians
were required to provide a ‘yes’ or ‘no’ answer
as to whether additional urological investiga-
tions were necessary following review of the
referral data on each case in the primary
evaluation. For patients designated ‘yes’, tests
and procedures could be chosen from a list of
investigations recommended in the AUA
guidelines for a urological work-up for a
patient with hematuria. Participant physicians
were also offered the option of requesting
additional tests or procedures not listed in the
standard protocol and offering further
comments.
For the purposes of this study, participant
physicians were instructed to consider all tests
and procedures to be fully funded, with no
additional cost incurred by the patient, to
remove any decision-making bias related to the
reimbursement status of any tests or procedures.
The participant physicians were able to ask
questions of the study coordinator regarding
each case, but no additional clinical back-
ground was provided beyond the case report
form. Participant physicians were not informed
of the final UC status of each case, nor were
they informed that all cases had been previously
selected for a urological work-up by a physician
in one of the participating physicians’ clinical
practices.
Participant physicians were then asked to
repeat their recommended clinical evaluation
for each case in the context of the information
derived from Cxbladder testing, firstly in the
Triage modality alone, and secondly when
results from both the Triage and Detect
modalities were provided. Cxbladder results
were presented in a format that was consistent
with the commercially available Cxbladder
tests, including a report outcome, explanation
of the Cxbladder test methodology [18, 19] and
guide to interpreting the results. Outcomes were
defined as ‘negative’ or ‘physician-directed
protocol’ in the Triage modality; and ‘normal’,
‘elevated’ or ‘high’ in the Detect modality. Par-
ticipant physicians were required to answer ‘yes’
or ‘no’ as to whether their clinical work-up and
management plan changed in light of each set
of Cxbladder test results.
Case Selection
To provide a fully representative cross-section of
patient demographics, cases were systematically
selected from the database of patients enrolled
in previous prospective clinical studies of
Cxbladder who met the AUA definition of
microhematuria with the possibility of UC
requiring a urological work-up, including inva-
sive diagnostic procedures [4]. All cases are
patients who had consented to the anonymous
use of their urine sample and clinical informa-
tion. Each anonymous case was assigned a ran-
dom case number after inclusion. Of the 40
available cases of patients with microhematuria
undergoing investigation for UC, 33 patient
cases met the study inclusion criteria (see
Appendix 1). Seven cases did not have sufficient
clinical information in their case report form to
fully support a decision on a recommended
clinical evaluation. Overall, the study generated
data from 792 decision nodes from 396 partici-
pant physician–patient case interactions.
Compliance with Ethics Guidelines
All cases selected for use in this study were
collected from patients who had provided
informed consent prior to being enrolled in
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clinical studies of Cxbladder. All data were col-
lected in accordance with all relevant ethical
guidelines. This article does not contain any
new studies with human or animal subjects
performed by any of the authors.
Study Participant Physicians
Twelve urologists from the USA (n = 5), New
Zealand (n = 4), Australia (n = 2) and Singapore
(n = 1) were invited to participate in the study
(see Appendix 2). Six participants practice in
public hospitals, four are in private practice and
two in tertiary referral centers and 6 are based in
public hospitals. Participant physicians had
prior experience in the use and application of
Cxbladder in real-world situations, either by
participating in clinical studies of Cxbladder or
as part of clinical diagnostic investigations for
real-world patients presenting with hematuria.
All participant physicians were offered hono-
raria to compensate for their time.
Study Endpoints
The co-primary endpoints were the changes in
both the total number of diagnostic procedures
used over all patient cases and the number of
invasive procedures requested following disclo-
sure of diagnostic information from Cxbladder
in the Triage and Triage and Detect modalities.
The co-primary endpoints were dependent on a
base assumption that all participant physicians
would recommend invasive diagnostic proce-
dures for all patients confirming the validity of
the sample of participating urologists. It was
expected that all selected patients should
receive at least one invasive procedure, in
accordance with the AUA guidelines and diag-
nostic procedures performed in the real world.
The relative proportion of patients not having
invasive diagnostic procedures requested by
US-based urologists versus non-US-based urolo-
gists was reviewed to investigate whether there
were any differences in diagnostic choice as a
result of region-specific practices.
Secondary endpoints included (1) the pro-
portion of patients with nil invasive procedures
requested following disclosure of diagnostic
information from Cxbladder tests in the Triage
modality and Triage and Detect modalities after
at least one invasive diagnostic procedure was
requested following primary evaluation, and (2)
the total number of procedures requested fol-
lowing disclosure of diagnostic information
from Cxbladder tests in the Triage modality and
Triage and Detect modalities.
Additional exploratory endpoints were
added when it became apparent that not all
participant physicians would recommend inva-
sive diagnostic procedures at primary evalua-
tion, including (1) the total number of invasive
diagnostic procedures either requested or
removed per participant physician, and (2) the
overall proportion of patients with at least one
invasive diagnostic test requested following
disclosure of diagnostic information from
Cxbladder in the Triage and Detect modalities
after non-invasive or no further diagnostic tests
were requested following primary evaluation.
Cystoscopy (flexible or rigid) and CT scans
(contrast or non-contrast) were defined as
invasive diagnostic procedures. Ultrasound,
urine cytology and UroVysion FISH were
defined as non-invasive procedures and tests.
RESULTS
Preliminary Evaluation of the Sample
Population Using Referral Data
In the context of initial evaluation data pro-
vided following referral, at least one invasive
diagnostic test was requested in 259/396
(65.4%) interactions. The proportion of cases in
which at least one invasive diagnostic proce-
dure was requested ranged from 15 to 97% of
patient cases for individual participant physi-
cians (see Appendix 3 for further information).
No differentiating pattern was observed
between US-based urologists and those from the
rest of the world, indicating no regional bias in
the selection of invasive diagnostic procedures
following primary evaluation, and enabling the
inclusion of all participating physicians in the
study.
A total of 689 diagnostic procedures were
requested following primary evaluations across
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the set of 396 participant physician–patient case
interactions. At least one additional diagnostic
test or procedure was requested for 24–100% of
patient cases evaluated. Of these procedures,
425 were classified as invasive, with individual
participant physicians applying a range of 5–67
invasive procedures across all patient cases.
Change in the Number of Invasive
Diagnostic Procedures Requested
with Disclosure of Information
from Cxbladder Tests
The total number of invasive diagnostic proce-
dures requested was reduced to 379 following
disclosure of information from Cxbladder in the
Triage modality alone, representing an 11%
reduction compared with primary evaluation of
the referral data (Fig. 1). The use of flexible
cystoscopy and CT scans was reduced by 19%
and 5%, respectively, while an increase in the
use rigid cystoscopy was reported in patients
with data available from Cxbladder in the
Triage modality (Fig. 1).
Following the disclosure of information from
Cxbladder in the Triage and Detect modalities,
292 invasive procedures were requested. This
represented a 31% reduction compared with
primary evaluation of the referral data. Specifi-
cally, the use of flexible cystoscopy and CT
scans was reduced by 44% and 20%, respec-
tively, and while the increased intention to use
a rigid cystoscopy following disclosure of results
from Cxbladder in the Triage modality was
maintained, fewer requests were made once
data from Cxbladder in the Detect modality was
also disclosed.
All participant physicians displayed a change
in their diagnostic behavior, either increasing or
decreasing the number of invasive procedures
in at least one case (Fig. 2). Overall, invasive
diagnostic tests were eliminated in 82 (31.7%)
interactions following the disclosure of addi-
tional diagnostic information provided to the
physicians from Cxbladder in the Triage and
Detect modalities (Fig. 2).
Change in the Number of Total Diagnostic
Procedures Requested with Disclosure
of Information from Cxbladder Tests
In several cases, participant physicians contin-
ued to use a similar work-up, but altered their
choice of procedure within that category fol-
lowing disclosure of information provided by
Cxbladder. The total number of diagnostic
Fig. 1 Overall number of invasive diagnostic procedures
requested by participant physicians across 396 participant
physician–case interactions after primary evaluation and
following disclosure of Cxbladder results in the Triage
modality and in the Triage and Detect modalities
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procedures was reduced to 657 following dis-
closure of Cxbladder results in the Triage
modality, representing a 5% reduction com-
pared with primary evaluation using referral
data (Fig. 1). Following subsequent disclosure of
Cxbladder results in the Detect modality in
addition to the Triage modality, the total
number of diagnostic procedures requested was
reduced to 514, representing a 25% reduction
compared with primary evaluation. In contrast,
the use of ultrasound was increased following
Cxbladder in the Triage modality (21%) and in
the Triage and Detect modalities (12%). A clin-
ically relevant reduction in the use of urine
cytology was observed (37%) (Fig. 1).
Change in the Number of Non-Invasive
Diagnostic Tests Requested
with Disclosure of Information
from Cxbladder Tests
No invasive diagnostic procedures were reques-
ted for 137/396 (34.5%) patient-by-physician
interactions in the context of primary evalua-
tion data (see Appendix 3 for further informa-
tion). Invasive diagnostic procedures were
requested following disclosure of information
from Cxbladder in the Triage and Detect
modalities for 21 (15.3%) of these interactions.
Selection of Invasive Diagnostic
Procedures for Patients with UC
The use of invasive diagnostic procedures that
aid in the detection of UC was more prevalent
amongst patients ultimately diagnosed with UC
following the addition of information from
Cxbladder tests. Following the primary evalua-
tion, at least one invasive diagnostic procedure
was selected for 16/24 (67%) case interactions
involving patients who were ultimately diag-
nosed with UC. Following disclosure of infor-
mation from Cxbladder in the Triage modality
and in the Triage and Detect modalities, the
proportion of invasive diagnostic procedures
requested increased to 24/24 (100%) case
interactions for patients ultimately diagnosed
with UC.
DISCUSSION
This is the first study to demonstrate the clinical
utility of a molecular diagnostic, non-invasive
Fig. 2 Change in requests for invasive diagnostic proce-
dures by individual participants after disclosure of Cxblad-
der results in both the Triage and Detect modalities
compared with requested invasive diagnostic procedures
following primary evaluation
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urine test in improving the management of
patients with asymptomatic hematuria by
focusing the diagnostic process on performing
appropriate procedures to improve clinical res-
olution. The use of Cxbladder reduced the total
number of procedures requested, including a
reduction in the number of invasive procedures,
resulting in improved outcomes for patients
with microhematuria referred to a urologist for
a urological work-up. The addition of Cxbladder
data changed clinical procedures allocated to
patients and enabled urologists to modify their
diagnostic procedures, resulting in the more
appropriate use of invasive procedures, partic-
ularly in all patients who had UC.
The clinical utility of diagnostic tests for
investigating the possibility of UC in patients
with hematuria is perhaps best defined by Sch-
mitz-Dra¨ger and colleagues [11] in the World
Health Organization/International Consulta-
tion on Urologic Diseases consensus manuscript
as providing ‘‘additional information that is
helpful to the clinician for the management of
the disease’’. A molecular diagnostic test should
also ‘‘be able to make the information available
in an efficient and timely manner’’ [11], which
is enabled by Cxbladder using a single urine
sample to evaluate patients with hematuria. All
urologists (100%) participating in this study
made clinically relevant changes to their diag-
nostic algorithm following the addition of
Cxbladder data used in both the Triage and
Detect modalities. The study also identified
wide physician variation in the clinical diag-
nostic algorithm between physicians. The level
of this variation was consistent between urolo-
gists and between countries, yet Cxbladder
facilitated all patients ultimately diagnosed
with UC being identified and referred for
appropriate invasive diagnostic procedures.
Until now, the clinical utility of molecular
diagnostic tests used in patients with hematuria
has been unclear, as early non-invasive urine
tests, currently available in the market, lack the
clinical resolution necessary for inclusion in
diagnostic guidelines [11]. Hematuria may be
caused by a number of diseases and conditions,
resulting in most patients being worked-up for
the possibility of UC in the absence of a
non-invasive urine test offering sufficient
clinical resolution to effectively triage out
patients with possible UC [11]. The outcome of
this study challenges the assertion that urolo-
gists should not pursue urine-based molecular
markers for UC detection in the initial evalua-
tion of hematuria [9].
Cxbladder is effective in ruling out patients
who have a low probability of UC in its Triage
modality [18]. Furthermore, its Detect modality
can also be applied to the same urine sample to
assess the risk of UC, and to segregate patients
accordingly [19]. The present study demon-
strates that Cxbladder overcomes concerns that
the use of molecular diagnostics in patients
with hematuria can lead to the detection of
more cases of UC, but only at the cost of
unnecessary invasive investigations [10]. Using
Cxbladder in the Triage and Detect modalities
in tandem may have utility in decreasing the
clinical burden on urologists and healthcare
systems by reducing the number of total pro-
cedures, including invasive procedures, per-
formed, while assisting with the accurate
detection of UC. Patients could also expect
fewer adverse events and improved quality of
life by avoiding invasive procedures [8, 12–17].
This study also represents a population-level
analysis of the impact of Cxbladder on treat-
ment decisions amongst patients with micro-
hematuria who are expected to have a low
prevalence of UC [21–24]. As demonstrated in
this study, when patients with the same char-
acteristics present to individual urologists, a
wide variation in diagnostic decisions may be
made. While demographic factors may influ-
ence the decision on how to work-up a patient
presenting with microhematuria, Cxbladder in
the Triage modality combines key risk factors,
i.e. gender, age and smoking history, with
genotypic data to support these decisions [18].
An earlier study has already demonstrated how
phenotypic risk factors are accounted for in
Cxbladder in the Triage modality, with a higher
proportion of patients with microhematuria
testing negative compared with patients with
macrohematuria [18]. Therefore, as evidenced
in this study by the differences in work-ups
chosen for patients ultimately diagnosed with
UC, additional information derived from
Cxbladder testing may not only lead to a more
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favorable outcome for the individual, but also
to an overall improvement in outcomes across a
population of urologists and patients, especially
when both tests are used in tandem. In partic-
ular, in this study, Cxbladder provided greater
clinical resolution, allowing physicians to
define a final clinical diagnostic algorithm to
best manage each patient. This results in a more
consistent approach to the use of invasive
diagnostic procedures, with urologists opting to
either increase or decrease their use appropri-
ately based on a patient’s risk and disease
prevalence (see Appendix 3).
The investigators considered the limitations
associated with the study design used here and
believed it to be the most pragmatic method of
evaluating the clinical utility of Cxbladder,
given the logistical, consistency and ethical
challenges in prospectively investigating the
selection of diagnostic tests in patients with
microhematuria by urologists in several coun-
tries. The results of this study provide data
justifying a prospective investigation of the
clinical utility of Cxbladder as a clinical inter-
vention in the diagnostic process. While the
present study is a retrospective analysis of a
prospectively recruited cohort of real-world
patients presenting for a urological work-up,
including invasive procedures, following a pri-
mary diagnosis of AMH without a clear benign
cause, this format has been effective in sup-
porting the hypothesis that Cxbladder used in
the Triage or Triage and Detect modalities may
improve the standard of care for patients pre-
senting with hematuria. By using a consistent
patient set across all participant physicians, the
investigators were able to limit the variance
between patients and focus on the variance
between physicians and their diagnostic algo-
rithms. The participant physicians evaluated
real-world patients who had been systemati-
cally selected for representation with real-
world referral data, on which to base their
decisions. Finally, all participant urologists
assessed the case studies in the same sequence,
which may increase the risk of bias if earlier
diagnostic decision-making was found to affect
decisions made in later cases. However, any
bias would be consistent across all participant
physicians.
CONCLUSIONS
Urologists make compelling changes to their
clinical decision-making behavior for patients
presenting with hematuria when presented
with Cxbladder results. The resultant increase in
clinical utility associated with Cxbladder is
characterized by the more appropriate alloca-
tion of invasive diagnostic procedures, resulting
in a reduction in both the total number of
diagnostic procedures and the number of inva-
sive procedures used, improving the diagnostic
experience for patients.
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